Literature DB >> 18493829

Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.

M Carlani1, S Mancino, E Bonanno, E Finazzi Agrò, G Simonetti.   

Abstract

PURPOSE: The objective of this study was to explore the feasibility of combined morphological magnetic resonance imaging (MRI), [(1)H]magnetic resonance spectroscopic imaging (MRSI) and quantitative dynamic contrast-enhanced MRI (DCE-MRI) of human prostate cancer at 3 Tesla using a pelvic phased-array coil.
MATERIALS AND METHODS: MRI, MRSI and DCE-MRI with a 3-Tesla whole-body scanner were performed in 30 patients with biopsy-proven prostate cancer before radical prostatectomy. High-resolution T2-weighted turbo spin echo (TSE) images were evaluated for visualisation of the peripheral zone, central gland, visibility of the cancer lesion, prostatic capsule delineation and overall image quality according to a five-point scale. Relative levels of the prostate metabolites citrate, choline and creatine were determined in cancer and in the normal peripheral zone (PZ) and central gland (CG). Spectra were also evaluated for the separation of the signal of citrate, choline and creatine and suppression of lipid and water signals. Time-intensity curves were obtained for prostatic cancer and healthy PZ and CG from DCE-MRI. Finally, time of arrival, time to peak, maximum enhancement and wash-in rate in cancer, normal PZ and CG were calculated.
RESULTS: The high signal-to-noise ratio (SNR) at 3 Tesla provided T2-weighted TSE images with excellent anatomical detail (in-plane voxel size of 0.22 x 0.22 mm) and good T2 contrast. The increased spectral resolution was sufficient to separate the choline and creatine resonances and allow delineation of the four peaks of citrate resonance. The (choline + creatine)/citrate ratio was elevated in cancer in comparison with PZ and CG (p<0.001). Dynamic contrast-enhanced images showed good temporal resolution. All parameters obtained from DCE-MRI showed a statistically significant (P<0.05) difference between cancer tissue and normal PZ and CG. Wash-in rate and (choline+creatine)/citrate ratio were significantly correlated (r=0.713, P=0.001) in PZ cancer, whereas the correlation was not significant (r=0.617, P=0.06) in CG and in PZ (r=0.530, P=0.08).
CONCLUSIONS: It is possible to perform MRI of prostate cancer at 3 Tesla using a pelvic phased-array coil with high spatial, temporal and spectral resolution. The combination of vascular information from DCE-MRI and metabolic data from MRSI has excellent potential for improved accuracy in delineating and staging prostate carcinoma. These results suggest that high magnetic field strengths offer the possibility of studying prostate cancer without use of an endorectal coil.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493829     DOI: 10.1007/s11547-008-0271-8

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  24 in total

1.  High-resolution intracranial and cervical MRA at 3.0T: technical considerations and initial experience.

Authors:  M A Bernstein; J Huston; C Lin; G F Gibbs; J P Felmlee
Journal:  Magn Reson Med       Date:  2001-11       Impact factor: 4.668

2.  Double inversion black-blood fast spin-echo imaging of the human heart: a comparison between 1.5T and 3.0T.

Authors:  Robert L Greenman; John E Shirosky; Robert V Mulkern; Neil M Rofsky
Journal:  J Magn Reson Imaging       Date:  2003-06       Impact factor: 4.813

3.  3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils; Initial experience(1).

Authors:  B Nicolas Bloch; Neil M Rofsky; Ronaldo H Baroni; Robert P Marquis; Ivan Pedrosa; Robert E Lenkinski
Journal:  Acad Radiol       Date:  2004-08       Impact factor: 3.173

4.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results.

Authors:  G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; S H Ruijs; J O Barentsz
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

5.  In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue.

Authors:  A Heerschap; G J Jager; M van der Graaf; J O Barentsz; J J de la Rosette; G O Oosterhof; E T Ruijter; S H Ruijs
Journal:  Anticancer Res       Date:  1997 May-Jun       Impact factor: 2.480

6.  Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study.

Authors:  U G Mueller-Lisse; D B Vigneron; H Hricak; M G Swanson; P R Carroll; A Bessette; J Scheidler; A Srivastava; R G Males; I Cha; J Kurhanewicz
Journal:  Radiology       Date:  2001-11       Impact factor: 11.105

7.  A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age.

Authors:  P A Bottomley; T H Foster; R E Argersinger; L M Pfeifer
Journal:  Med Phys       Date:  1984 Jul-Aug       Impact factor: 4.071

8.  Invasion of the neurovascular bundle by prostate cancer: evaluation with MR imaging.

Authors:  C M Tempany; A D Rahmouni; J I Epstein; P C Walsh; E A Zerhouni
Journal:  Radiology       Date:  1991-10       Impact factor: 11.105

9.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.

Authors:  J Kurhanewicz; D B Vigneron; H Hricak; P Narayan; P Carroll; S J Nelson
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

10.  Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI.

Authors:  Fabian Kiessling; Matthias Lichy; Rainer Grobholz; Melanie Heilmann; Nabeel Farhan; Maurice Stephan Michel; Lutz Trojan; Joerg Ederle; Ulrich Abel; Hans-Ulrich Kauczor; Wolfhard Semmler; Stefan Delorme
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

View more
  7 in total

Review 1.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

Review 2.  Metabolic Imaging in Humans.

Authors:  Taylor L Fuss; Leo L Cheng
Journal:  Top Magn Reson Imaging       Date:  2016-10

3.  A PET/CT Directed, 3D Ultrasound-Guided Biopsy System for Prostate Cancer.

Authors:  Baowei Fei; Viraj Master; Peter Nieh; Hamed Akbari; Xiaofeng Yang; Aaron Fenster; David Schuster
Journal:  Prostate Cancer Imaging (2011)       Date:  2011

4.  Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA).

Authors:  V Panebianco; A Sciarra; M Ciccariello; D Lisi; S Bernardo; S Cattarino; V Gentile; R Passariello
Journal:  Radiol Med       Date:  2010-09-17       Impact factor: 3.469

Review 5.  A decade in prostate cancer: from NMR to metabolomics.

Authors:  Elita M DeFeo; Chin-Lee Wu; W Scott McDougal; Leo L Cheng
Journal:  Nat Rev Urol       Date:  2011-05-17       Impact factor: 14.432

6.  MR Spectroscopic Imaging of Peripheral Zone in Prostate Cancer Using a 3T MRI Scanner: Endorectal versus External Phased Array Coils.

Authors:  Rajakumar Nagarajan; Daniel Ja Margolis; Steven S Raman; David Ouellette; Manoj K Sarma; Robert E Reiter; M Albert Thomas
Journal:  Magn Reson Insights       Date:  2013-05-15

Review 7.  Focal therapy for prostate cancer: revolution or evolution?

Authors:  Ryan Turpen; Charles J Rosser
Journal:  BMC Urol       Date:  2009-04-23       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.